Savient Pharmaceuticals Files For Ch. 11, Plans $55M Sale

Law360, Wilmington (October 15, 2013, 5:01 PM EDT) -- Cash-strapped drug developer Savient Pharmaceuticals Inc. filed for Chapter 11 in Delaware bankruptcy court on Monday, seeking to sell its assets to a unit of US WorldMeds LLC, which has signed on as a $55 million stalking-horse bidder.

New Jersey-based Savient — which posted roughly $73.8 million in assets against nearly $260.4 million in liabilities as of June 30 — and its sole U.S. subsidiary sought court protection after the drug developer's flagship product Krystexxa failed to carry the company to profitability.

Savient saw its cash...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.